ARTICLE SUMMARY:
Medtech stocks are down roughly 20% so far this year, slightly more than the S&P, jolted, as are other industries, by uncertainties over COVID-19 and inflation. Drivers of medical device stocks this year center on companies’ top-line growth, propelled by market share and/or revenue gains, according to BTIG Managing Director Ryan Zimmerman.
After years of above average returns, medical device stocks are down collectively by roughly 20% over the past six months, slightly more than the decline of the S&P 500. Even as reality sets in that 
COVID-19 and hospital staffing shortages are likely to continue for some time, it’s not yet a bear market, says Ryan Zimmerman, managing director and senior medtech analyst for BTIG. He says some elective surgery-heavy subsectors are thriving despite the headwinds and expects to see a step up in M&A this year.
Subscribers can watch our video interview with Ryan Zimmerman below.
